Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer.
Kim J, Park KE, Jeong YS, Kim Y, Park H, Nam JH, Jung K, Son WS, Jung HS, Lee JH, Jeong SH, Kim NA, Ha JD, Cho SY, Choi YL, Chung SJ, Choi JY, Hong S, Shin YK.
Kim J, et al. Among authors: son ws.
Cancers (Basel). 2020 Jun 15;12(6):1575. doi: 10.3390/cancers12061575.
Cancers (Basel). 2020.
PMID: 32549194
Free PMC article.